Immunic Therapeutics

NEWS

Multiple sclerosis damaged myelin or MS autoimmune disease with healthy nerve with exposed fibre with scarrred cell sheath loss as a 3D illustration.

Beyond BTK Inhibitors: Next Gen MS Treatments Could Transcend Symptom Management

While Bruton’s tyrosine kinase inhibitors are often hailed as the next big breakthrough in multiple sclerosis, Immunic Therapeutics and others are leveraging neuroprotective targets and remyelination to keep the disease at bay.

October 6, 2025

5 min read

Ben Hargreaves

IN THE PRESS

Business

Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024

14 min read

Pharm Country

Immunic to Participate in Investor and Scientific Conferences in May 2024

May 6, 2024

6 min read

Business

Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update

May 1, 2024

5 min read

Drug Development

Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation

April 30, 2024

10 min read

Pharm Country

Immunic to Host MS R&D Day and Participate in Investor Conferences in April 2024

April 4, 2024

5 min read

Pharm Country

Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States

March 20, 2024

8 min read

Pharm Country

Immunic to Participate in Investor and Scientific Conferences in March 2024

March 7, 2024

6 min read

Pharm Country

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update

February 15, 2024

5 min read

Pharm Country

Immunic to Participate in Investor and Scientific Conferences in February

February 1, 2024

5 min read

Pharm Country

Immunic, Inc. Announces Private Placement of up to $240 Million

January 5, 2024

8 min read

JOBS